Sonnet BioTherapuetics(SONN)

Search documents
Sonnet BioTherapuetics(SONN) - 2023 Q1 - Quarterly Report
2023-02-13 13:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jur ...
Sonnet BioTherapuetics(SONN) - 2022 Q4 - Annual Report
2022-12-15 21:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2932652 (State or Oth ...
Sonnet BioTherapuetics(SONN) - 2022 Q3 - Quarterly Report
2022-08-15 20:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Juris ...
Sonnet BioTherapuetics(SONN) - 2022 Q2 - Quarterly Report
2022-05-10 11:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2932652 ...
Sonnet BioTherapuetics(SONN) - 2022 Q1 - Quarterly Report
2022-02-08 11:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) Delaware 20-2932652 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-3557 ...
Sonnet BioTherapuetics(SONN) - 2021 Q4 - Annual Report
2021-12-17 01:44
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-2932652 (State or oth ...
Sonnet BioTherapuetics(SONN) - 2021 Q3 - Quarterly Report
2021-08-16 11:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in the charter) (State or other jurisdiction of ...
Sonnet BioTherapuetics(SONN) - 2021 Q2 - Quarterly Report
2021-05-17 12:30
Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in the charter) incorporation or organization) Identification Number) Delaware 20-2932652 (State or other jurisdiction of (I.R.S. Employer 100 Overlook Center, Suite 102, Princeton, NJ 0 ...
Sonnet BioTherapuetics(SONN) - 2021 Q1 - Quarterly Report
2021-02-16 12:57
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, $0.0001 Par Value | SONN | The Nasdaq ...
Sonnet BioTherapuetics(SONN) - 2019 Q2 - Earnings Call Transcript
2019-08-15 02:57
Chanticleer Holdings, Inc. (BURG) Q2 2019 Results Earnings Conference Call August 15, 2019 4:30 PM ET Company Participants Jason Assad - Head of IR Michael Pruitt - Chairman and CEO Patrick Harkleroad - CFO Fred Glick - President Conference Call Participants David Burdick - Oak Ridge John O'Shea - Global Alliance Operator Welcome to the Chanticleer HoldingsÂ' Q2 2019 Conference Call. As a reminder, all participants are in a listen-only mode and the conference is being recorded. At this time, I would like to ...